Premium
P4‐308: Antipsychotic drug use in patients with Alzheimer's disease treated with Rivastigmine versus donepezil: Evidence from health claims data
Author(s) -
Scharre Douglas W.,
Lefebvre Patrick,
Vekeman Francis,
Foreix Julien,
Kahler Kristijan H.,
Turk Florian,
Duh Mei S.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.2378
Subject(s) - donepezil , rivastigmine , medicine , antipsychotic , dementia , galantamine , psychiatry , schizophrenia (object oriented programming) , disease
(SAD) were used for studies on mechanism of PN401 action. Results: Female APPswe P301L (TAPP) mice that began PN401 treatment at 5 months of age had improved social transmission of food preference at 7 and 12 months. PN401 treatment also improved novel object recognition at 7 and 13 months of age. TAPP mice given PN401 treatment improved motor learning on the accelerated rotarod as compared to TAPP control mice. PN401 given for two months starting at 4 months of age in female Tg2576 APPswe mice improved contextual fear memory that was impaired in 6-month old Tg2576 control mice. Further biochemical and histological analysis of these mice is underway. The mechanism for the improvement in memory in the mouse models of AD due to PN401 may include reduced oxidative stress evident by a reduction in urinary isoprostane F2 . Studies in SH-SY5Y cells indicate that uridine can increase sAPP secretion, enhance neurite outgrowth and reduce ROS formation. Uridine (20-200 M) was also shown to protect fibroblasts from AD patients in a chemical hypoxia model. Conclusions: PN401 is an oral drug that may be beneficial in treatment of multiple etiological factors associated with AD.